Dyadic Reports 2022 Year End Results and Recent Company Progress
29 mars 2023 16h00 HE
|
Dyadic International, Inc.
Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding...
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
15 mars 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic to Participate in Two Upcoming Investor Conferences
02 févr. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Announces Sale of Equity Interest in Alphazyme
19 janv. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
YMAB Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Y-mAbs Therapeutics, Inc.
11 nov. 2022 20h00 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the...
Dyadic to Present at Upcoming Industry and Investor Events in September
08 sept. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®
13 juil. 2022 13h32 HE
|
QSAM Biosciences, Inc.
AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- via Investorwire -- QSAM Biosciences Inc. (OTCQB: QSAM) (the “Company”), a company developing next-generation targeted therapeutic...
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
05 juil. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment
26 sept. 2019 08h30 HE
|
Genprex Inc Registered Shs
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – GNPX)">Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with...
Makati Medical Center in the Philippines Adopts Precipio’s ICE COLD-PCR Mutation Enrichment Technology for Liquid Biopsies
15 janv. 2019 07h47 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that Makati Medical Center (MakatiMed) in Manila, the Philippines,...